INTRODUCTION {#S5}
============

Both prospective epidemiology studies and intervention studies have shown that plasma C-reactive protein (CRP) levels, a marker of systemic inflammation, are associated with incidence of cardiovascular disease (CVD), independently from other conventional risk factors ([@R7]). Studies have also reported an association between plasma CRP levels and diabetes incidence ([@R8]). Based on these observations, correlates of plasma CRP levels need to be better established in order to potentially target the determinants of plasma CRP levels and hopefully reduce its related risk of CVD/diabetes. Although obesity, particularly abdominal obesity is associated directly with plasma CRP levels ([@R12], [@R15]) the variance in CRP accounted for by weight is relatively small. It is increasingly recognized that specific dietary patterns are associated with plasma CRP levels ([@R16]). However, these dietary patterns remain poorly investigated.

In the Western world, coffee consumption is ubiquitous and represents the only liquid, other than water, that is consumed almost everyday by a majority of adults ([@R20]). Coffee consumption has been associated with a decreased risk of type 2 diabetes, CVD, breast cancer and inflammatory diseases ([@R1], [@R9], [@R18], [@R22]). Despite these observations, the exact mechanisms for these associations remain largely unexplained. Additionally, there is limited evidence to suggest that coffee consumption is associated with lower CRP levels ([@R10], [@R13]). Conversely, it has been shown that postmenopausal women using hormone replacement therapy (HRT) are characterized by higher plasma CRP levels ([@R17]). Whether coffee consumption would alter the relationship between BMI and CRP in postmenopausal women using or not using HRT is unknown.

The objective of the present study was to examine the relationship between coffee consumption, obesity and plasma CRP levels in a sample of overweight/obese, postmenopausal women and to investigate whether HRT might alter these associations.

MATERIALS AND METHODS {#S6}
=====================

Study Design {#S7}
------------

The present analyses were conducted on the baseline examination data of postmenopausal women enrolled in the Dose-Response to Exercise in postmenopausal Women (DREW) trial. A complete description of DREW design and methods has been previously reported ([@R5], [@R14]). The study was a randomized, dose-response exercise trial with a no-exercise control group and 3 exercise groups with incrementally higher doses of energy expenditure. The results of the primary endpoints of this protocol have been previously published ([@R5]). We certify that all applicable institutional regulations concerning the ethical use of human volunteers were followed during this research. The research protocol was reviewed and approved annually by the Cooper Institute\'s institutional review board and subsequently approved by the Pennington Biomedical Research Center IRB for the continued analysis and publication of relevant research findings. Written informed consent was obtained from all participants prior to their inclusion in the study.

Study Participants {#S8}
------------------

A total of 4545 telephone screening interviews between April 2001 and June 2005 were conducted, which ultimately resulted in enrolling 464 postmenopausal, sedentary, overweight/obese \[body mass index (BMI) of 25.0--43.0 kg/m^2^\] women aged 45 to 75 years with elevated blood pressure (systolic blood pressure (SBP) ranging from 120.0 to 159.9 mmHg). Exclusion criteria included history of stroke, heart attack, or any serious medical condition that prevented participants from adhering to the protocol or exercising safely. Women were excluded from this study if they had significant cardiovascular disease or disorders (including but not limited to arrhythmias, myocarditis, cardiomyopathy, congestive heart failure, heart disease, stroke or transient ischemic cerebral attacks, peripheral vascular disease with intermittent claudication, acute, chronic or recurrent thrombophlebitis). Women were also excluded if they had a 10-year risk above 10% as indicated by NCEP Panel III report. Diet was assessed once at the beginning of the study using the Food Intake Analysis System semi-quantitative food frequency questionnaire ([@R21]). Women reporting taking HRT were on a stable dose for a minimum of 6 months.

Plasma CRP levels were measured by a highly sensitive immunoassay that used monoclonal antibodies coated with polystyrene particles. The assay was performed with a Behring BN-100 nephelometer (Dade Behring) according to the methods described by the manufacturer ([@R11]). The coefficient of variation for C-reactive protein in this analysis was 1.0. Individuals with missing coffee data (n=9), who smoked (n=27), taking statins (n=75) or with missing hormone therapy data (n=7) were excluded resulting in 344 individuals with complete data.

Weight was measured on an electronic scale (Siemens Medical Solutions, Malvern, PA) and height was measured using a standard stadiometer. This scale was calibrated weekly. BMI was calculated as weight in kilograms divided by height in meters squared. Cardiorespiratory fitness was measured using a Lode Excalibur Sport cycle ergometer as previously described ([@R5]). Blood pressure was measured after a 30 minute rest period using a Colin STBP-780 automated blood pressure unit with participants in the recumbent position.

Statistical analyses {#S9}
--------------------

Women were categorized based on coffee consumption into the following groups: no coffee consumption, 1 cup/month to 6 cups/week, 1 cup/day to 13 cups/week or ≥2 cups/ day. We computed the arithmetic mean and standard deviation of each variable by categories of coffee consumption. For dichotomous variables we calculated percentages. Due to the skewed distribution of CRP, we log-transformed CRP values for statistical analyses based on the general linear model, with results expressed as geometric means. We compared geometric mean CRP values across categories of coffee consumption with progressively increased adjustment. Model 1 was adjusted for age. Model 2 was further adjusted for hormone replacement therapy. Model 3 was further adjusted for ethnicity and model 4 was further adjusted for BMI, fitness, alcohol use and arthritis. Because individuals who consumed no coffee had a similar mean CRP as individuals who consumed 1 cup/month to 6 cups/week, we collapsed these two coffee intake categories. We also examined the geometric mean CRP across levels of either BMI or coffee consumption in women using and not using HRT and tested the differences between each group using general linear models. We categorized individuals as overweight (25.0 kg/m^2^ ≤ BMI \<30.0 kg/m^2^) obese class I (30.0 kg/m^2^ ≤ BMI \<35.0 kg/m^2^) or obese class II or above (BMI ≥35.0 kg/m^2^) using established cut-offs. Using linear regression models, we examined the association between BMI and transformed CRP values within levels of coffee consumption in women using and not using HRT. The significance of interactions was assessed by multiple regression analyses. All analyses were performed using commercially available software.

RESULTS {#S10}
=======

Baseline anthropometric and metabolic characteristics are presented in [Table 1](#T1){ref-type="table"} for the whole sample and across levels of coffee consumption. Participants included in the present study were apparently healthy middle-aged obese women. One hundred and sixty (47%) women reported to be currently using HRT. Higher levels of coffee consumption were associated with older age and being Caucasian. None of the other CVD risk factors nor anthropometric measures were associated with coffee consumption. Across coffee consumption categories, women who reported using hormone replacement therapy had similar BMI adiposity indices (data not shown).

[Table 2](#T2){ref-type="table"} shows median and mean plasma CRP levels across levels of coffee consumption. Greater coffee consumption was significantly associated with lower CRP levels (p for trend = 0.002). Further adjustment for potential confounders including age, BMI, hormone replacement therapy, ethnicity, fitness, alcohol use and arthritis had no meaningful effect on the association (p for trend=0.005). We have studied the relationship of CRP several other dietary component (total energy intake, alcohol intake, saturated fat intake and fiber intake) and found that only coffee intake was associated with CRP (data not shown).

[Figure 1](#F1){ref-type="fig"} depicts plasma CRP levels in women classified on the basis of BMI and HRT use. In women using or not using HRT, CRP was positively associated with BMI (p for trend \< 0.001 for each). [Figure 2](#F2){ref-type="fig"} shows plasma CRP levels in women classified on the basis of coffee consumption and HRT use. As reported in [Table 2](#T2){ref-type="table"}, women with an elevated coffee consumption had lower plasma CRP levels. In women using and not using HRT, CRP was inversely associated with coffee consumption (P trend = 0.02 and 0.05, respectively).

[Figure 3](#F3){ref-type="fig"} depicts the BMI and CRP relation within levels of coffee consumption in women not using HRT (top) and using HRT (bottom). In women using HRT, there was a positive relationship between BMI and CRP levels for all three coffee consumption categories. In women not using HRT, there was a positive association between BMI and CRP in women that drank \<1 cup of coffee per day. Using a formal test for interaction, we found no association between BMI and CRP in women that do not use HRT and drink one or more cups of coffee per day (p=0.62). In women not using HRT, the coffee-by-BMI interaction analysis just missed obtaining statistical significance (p = 0.08).

DISCUSSION {#S11}
==========

Results of the present study suggest that the relationship between obesity and plasma CRP levels is influenced by coffee consumption in overweight/obese, postmenopausal women who do not use HRT. As the positive relationship between obesity and plasma levels of CRP has been well-described in several studies, we found that, in women who reported drinking at least one daily cup of coffee, BMI was not associated with CRP. However, our results also suggest that this observation is limited to postmenopausal women who do not use HRT. As approximately half of postmenopausal U.S. women report using HRT ([@R2]), we believe that these findings could have an important impact in terms of chronic diseases prevention. Indeed, it is well recognized that women using HRT are characterized by increased plasma CRP levels ([@R6], [@R17]). In our study, we found that this relationship was also independent from coffee consumption. Although the joint effects of obesity and HRT (or oral contraceptives) on plasma CRP levels have been previously documented ([@R3]), our study suggests that coffee consumption might modify these relationships. To the best of our knowledge, the present study is the first ever conducted on this topic.

A few studies have investigated the association between coffee consumption and low-grade inflammation biomarkers such as CRP. In the ATTICA study, Zampelas and colleagues ([@R24]) investigated the relationship between coffee consumption and inflammatory markers in 1528 apparently healthy women (mean age=45±13 years) and reported that coffee consumption was positively associated with CRP levels. In that study, compared to women who did not drink coffee, those who consummated more than 400 mL/day had approximately 38% higher CRP levels. However, it is worth mentioning that although CRP levels were higher, mean plasma levels of CRP women drinking more than 400 mL/day remained in what is considered as a "normal" CRP range. The fact that our study population was limited to overweight/obese postmenopausal women compared to a study sample representative of women living in a Greek province (Attica) might explain, to a certain extent, this discrepancy. Similarly to what we observed in the present study, results of the Nurses' Health Study suggest that plasma CRP levels were lower in women who reported drinking more than two cups of coffee per day compared with women who reported drinking less than one cup of coffee per day ([@R13]). However, this observation was limited to women with type 2 diabetes as healthy women had similar CRP levels across coffee consumption categories. It is of interest to mention that diabetic women of that cohort had BMIs and blood pressure values which were similar to those assessed in our study sample. Finally, in a sample of 459 community-living Japanese women aged 23--83, Kotani et al. ([@R10]) reported that CRP was lower in women who reported consuming at least one cup of coffee per day compared to women who consumed less than one cup of coffee per day. Although they mentioned that this difference was higher in women aged \>60 years of age, they did not investigate whether this relationship was still observed in women using or not using HRT.

Over the past few years, studies have reported that coffee consumption was associated with a lower risk of type 2 diabetes an inflammatory diseases in women ([@R1], [@R23]). However, very few studies have examined how this relationships could be explained from a pathophysiological standpoint. Chung et al. ([@R4]) have shown that treatment of HepG2 cells with caffeic acid, a naturally occurring phenolic compound found in coffee might inhibit the function of the transcription nuclear factor κB, an important mediator of the inflammatory response. Although coffee might have anti-inflammatory or anti-oxidation properties, there is little pathophysiological evidence to support the results observed in the present study. Moreover, whether the relationship between HRT and CRP is the consequence of increased systemic inflammation or rather the consequence of the effects of estrogens on hepatic CRP production remains unclear ([@R17], [@R19]) and the possible biological pathways though which coffee might alter the relationship between obesity and CRP in postmenopausal women who do not use HRT need to be established.

Because of the cross-sectional design of our study, we cannot infer causality from our results. The prospective relationship between obesity, coffee consumption and plasma CRP levels and associated CVD and type 2 diabetes risk should be further investigated in population and/or intervention studies. Moreover, as our study sample was limited to overweight/obese postmenopausal women, we believe that this relationship should be documented in nonobese women from various ethnicities as well as in men. Similarly, since our study population was limited in size, lack of statistical power may have limited our ability to detect associations, especially for the analyses which required separating the study population into six groups. One other limitation of our study is the fact that coffee consumption was self-reported and that the food frequency questionnaire that was used did not enable us to measure the intake of the principal bioactive component of coffee: caffeine. Women of the study took the questionnaire once at the beginning of the study and therefore, we could not perform repeated assessment of coffee intake. Finally, the difference between consumption of boiled vs. filtered coffee was not assessed. However, these limitations would introduce an increased random measurement error that would likely attenuate the associations reported in the present study.

In conclusion, we found that BMI was positively associated with variations in plasma CRP levels and that coffee consumption was inversely associated with CRP, more specifically in overweight/obese postmenopausal women who did not take HRT. Our study also suggests that coffee consumption alters the relationship between obesity and plasma CRP levels in these women. In women who reported using HRT, BMI was positively associated with plasma CRP levels, with coffee consumption having no impact on this relationship. As the relationship between coffee consumption and CVD risk is not fully established, results of the present study do not support the view that coffee consumption could be deleterious to cardiovascular health. Rather, based on the results of our study, coffee consumption is associated with reduced levels of an inflammatory marker predictive of CVD risk in overweight/obese postmenopausal women who do not use HRT. However, whether coffee consumption should be encouraged to reduce CVD and/or type 2 diabetes risk associated with low-grade inflammation still needs to be further investigated. Additional studies and randomized trials will shed light on the specific mechanisms by which coffee consumption could possibly be linked to low-grade inflammation.
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###### 

Baseline Participant Characteristics[\*](#TFN2){ref-type="table-fn"}

                                                            Coffee Consumption                                                               
  --------------------------------------------------------- -------------------- -------------- -------------- -------------- -------------- ---------
  Age, y                                                    57.1 (6.4)           55.5 (6)       55.8 (6)       59.2 (6.2)     58.7 (6.7)     \<0.001
  Ethnicity, %                                                                                                                               
    Caucasian                                               64.8                 52.0           53.5           72             90.8           \<0.001
    African American                                        28.2                 39             39.5           19             7.7            
    Hispanic/other                                          7                    9              7              9              1.5            
  Current hormone therapy, %                                46.5                 43.3           47.7           49.4           46.2           0.85
  Arthritis, %                                              27                   23.1           23.3           38.2           23.1           0.06
  Alcohol use, g/day                                        1.7 (2.4)            1.2 (2)        1.9 (2.4)      1.9 (2.6)      1.7 (2.4)      0.17
  Weight, kg                                                84.0 (12.1)          84 (12.5)      85.2 (11.3)    83.3 (12.8)    83.6 (11.6)    0.75
  Waist circumference, cm                                   100.6 (12.2)         101.1 (11.3)   99.9 (12.3)    101.6 (13.7)   99.2 (11.3)    0.59
  Body mass index, kg/m^2^[†](#TFN3){ref-type="table-fn"}   31.6 (3.9)           31.6 (3.8)     31.9 (3.4)     31.5 (4.3)     31.5 (3.6)     0.87
  Cardiorespiratory fitness, ml/kg per min                  15.4 (3.2)           15.1 (3.2)     15.9 (3.1)     15.6 (2.9)     15.0 (3.8)     0.27
  LDL-C, mg/dL                                              121.0 (26.5)         122.9 (24.7)   122.8 (26.3)   118.3 (26)     119.0 (30)     0.52
  HDL-C, mg/dL                                              58.5 (14.8)          57.3 (12.4)    58.0 (12.9)    60.1 (16.8)    58.8 (17.3)    0.61
  Triglycerides, mg/dL                                      130.1 (66.9)         128.9 (65.1)   130.0 (58.9)   129.0 (75.6)   133.5 (68.6)   0.97
  Fasting glucose, mg/dL                                    94.4 (9.8)           92.6 (10.7)    95.1 (10.2)    95.1 (9)       95.5 (8.5)     0.14
  Blood pressure, mm Hg                                                                                                                      
    Systolic                                                140.6 (13.1)         138.8 (12.6)   140.5 (11.4)   140.6 (13.3)   143.8 (15.4)   0.12
    Diastolic                                               81.5 (8.4)           81.3 (8)       83.8 (7.5)     80.3 (9.5)     80.5 (8.2)     0.02

Abbreviations: LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HR, heart rate; VO~2~, volume of oxygen consumed

Continuous variables presented as means (SD) and dichotomous variables presented as percentages.

Calculated as weight in kilograms divided by height in meters squared

For between group differences

###### 

C-reactive protein across categories of coffee consumption.

                                     Coffee Consumption                                         
  ---------------- ----------------- -------------------- ------------------ ------------------ -------
  Median CRP       5.0 \[1.7,8.7\]   5.3 \[2.4, 9.3\]     3.3 \[1.4, 7.7\]   3.1 \[1.7, 5.5\]   N/A
  **Covariates**                                                                                
  None             4.1 (3.3, 5.0)    4.3 (3.4, 5.4)       3.2 (2.5, 3.9)     2.9 (2.2, 3.6)     0.002
  Model 1          4.1 (3.4, 5.0)    4.2 (3.4, 5.2)       3.2 (2.6, 3.9)     2.9 (2.2, 3.7)     0.002
  Model 2          4.2 (3.5, 5.1)    4.2 (3.4, 5.1)       3.1 (2.5, 3.8)     2.9 (2.3, 3.6)     0.001
  Model 3          4.1 (3.4, 5.0)    4.1 (3.3, 5.0)       3.1 (2.6, 3.9)     3.0 (2.4, 3.8)     0.005
  Model 4          4.1 (3.4, 4.9)    4.1 (3.3, 5.0)       3.1 (2.6, 3.8)     3.0 (2.4, 3.8)     0.005

Geometric means with adjustment for CRP levels are shown. Model 1 was adjusted for age and BMI. Model 2 was further adjusted for hormone replacement therapy. Model 3 was further adjusted for ethnicity and model 4 was further adjusted for fitness, alcohol use and arthritis. Data is expressed as mean (95% CI) or median (IQR).
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